PARP inhibitors
Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses
Early data on AZD5305 showed it is highly tolerable and suggested it may be amenable to combination and prevention strategies.
UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study
Research into cancer interception tactics still have a long way to go, but studies like that of Inovio's INO 5401 could offer a framework, a prominent cancer researcher suggested at AACR.
MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients
The bioinformatics startup will work with Macrogen Europe to develop an AI-based tool for analyzing WGS data to identify patients who should receive PARP inhibitors.
Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response
The collaboration between Mass General and Switzerland's Lunaphore will initially focus on developing a test for ovarian, breast, and prostate cancers.
Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute
The firm plans to develop novobiocin for homologous recombination-deficient cancers including those resistance to PARP inhibitors.